Company news
Hunan Fangsheng Pharmaceutical Co., Ltd. Class A (SSE:603998) news
Hunan Fangsheng Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 24, 2025: Announcement on Obtaining Summary Report of Phase II Clinical…
Press releases — page 2
Announcement on Obtaining Summary Report of Phase II Clinical Trial for Zhilong Tongluo Tablets
September 23, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025
September 11, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trials by A Holding Subsidiary for Traditional Chinese Medicine Innovative Drug Research Project
September 4, 2025
Announcement on Outline of the 2025 Semi-annual Performance Briefing
August 29, 2025
2025 Semi-annual Report
August 28, 2025
Announcement on Progress in the Sale of Partial Equity in Investment Projects by the M&A Fund Participated and Established by the Company
August 25, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 21, 2025
Announcement on Providing Non-financing Guarantee for Holding Subsidiary
August 19, 2025
Announcement on Progress in Matters Related to Actual Controller
August 7, 2025
Announcement on Progress in Acquiring Pharmaceutical Production Technology
July 22, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trials by Subsidiary for Traditional Chinese Medicine Innovative Drug Research Project
July 11, 2025
Announcement on Progress of Drug Marketing Authorization Transfer
June 20, 2025
Announcement on Obtaining Drug Registration Certificate for Innovative Traditional Chinese Medicine Yangxue Qufeng Zhitong Granules
June 9, 2025
Announcement on Capital Increase to Holding Subsidiary and Related Party Transactions
June 3, 2025
Announcement on Implementation of Dividend Distribution for 2024
June 2, 2025
Announcement on the Progress of Transferring Partial Equity of Holding Subsidiaries and Introducing Strategic Investors
May 21, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 20, 2025
Announcement on Results of Share Increase by Persons Acting in Concert with Controlling Shareholder
May 14, 2025
Announcement on the Implementation of Repurchase and Cancellation of Equity Incentive Restricted Stock
May 12, 2025
Announcement on Resolutions of the 3rd Extraordinary Meeting of the 6th Board of Supervisors in 2025
May 8, 2025